Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 22,184 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 22,184 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.50, for a total value of $11,092.00. Following the completion of the sale, the director directly owned 1,104,312 shares in the company, valued at approximately $552,156. The trade was a 1.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total value of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $28,336.50.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total value of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62.

Werewolf Therapeutics Stock Up 2.2%

Shares of NASDAQ HOWL traded up $0.01 during trading hours on Wednesday, reaching $0.44. 1,033,082 shares of the stock traded hands, compared to its average volume of 460,756. The company has a market capitalization of $21.29 million, a P/E ratio of -0.35 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $2.38. The company’s 50-day simple moving average is $0.80 and its two-hundred day simple moving average is $0.79.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC grew its position in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the last quarter. Citadel Advisors LLC bought a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $304,000. Jane Street Group LLC bought a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Vanguard Group Inc. grew its position in Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on HOWL. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.